Luxna Biotech

Develops nucleic acid medicines based on bridged modified nucleic acids (XNAs) that bind strongly to target mRNA and reduce liver toxicity risk, addressing safety and efficacy challenges in nucleic acid drug development and enabling altered delivery beyond liver and kidney. Sells to pharmaceutical companies and academic drug discovery researchers on a B2B basis. Positioned on licensed XNA chemistry from Osaka University that enables antisense design with improved binding and lower toxicity compared with conventional nucleic acid approaches.

Key features

• Joint drug discovery with pharma companies
• XNAs technology licensing
• In-house nucleic acid drug development
• XNAs monomer supply
• Bridged modified nucleic acid design
• Antisense design with bridged nucleic acids
• Strong binding to target mRNA
• Reduced hepatotoxicity risk technology
• Altered tissue delivery potential